Ionis Pharmaceuticals
IONS
Market cap $5.33B

33.50 USD

-0.97

2.81%

At close May 21, 4:00 PM EDT

Pre-market

34.15

+0.65

1.94%

1 day

-2.81%

5 days

2.54%

1 month

17.50%

3 months

3.65%

6 months

-1.30%

Year to date

-3.43%

1 year

-10.36%

5 years

-38.31%

10 years

-42.09%

About: Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Employees: 927

Healthcare Biotechnology

0

Funds holding %

of 7,245 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

50% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 6 (+2) [Q1 2025]

32% more call options, than puts

Call options by funds: $24.8M | Put options by funds: $18.8M

2.69% more ownership

Funds ownership: 101.63% [Q4 2024] → 104.31% (+2.69%) [Q1 2025]

4% less funds holding

Funds holding: 351 [Q4 2024] → 336 (-15) [Q1 2025]

11% less capital invested

Capital invested by funds: $5.61B [Q4 2024] → $5.01B (-$606M) [Q1 2025]

13% less first-time investments, than exits

New positions opened: 52 | Existing positions closed: 60

18% less repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 123

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$39

16%

upside

Avg. target

$51

51%

upside

High target

$64

91%

upside

5 analyst ratings

3 positive

60%

2 neutral

40%

0 negative

0%

HC Wainwright & Co. Mitchell Kapoor	49%upside $50	Buy Reiterated	20 May 2025
Guggenheim Debjit Chattopadhyay	91%upside $64	Buy Maintained	1 May 2025
Needham Joseph Stringer	64%upside $55	Buy Maintained	30 Apr 2025
Redburn Atlantic Joshua Smith	16%upside $39	Neutral Initiated	31 Mar 2025
JP Morgan Jessica Fye	34%upside $45	Neutral Maintained	24 Mar 2025

See Analyst Rankings

Financial journalist opinion

Based on 12 articles about IONS published over the past 30 days

Zacks Investment Research

Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study

Late-stage data shows that treatment with an 80mg dose of IONS' Tryngolza achieved a 61% placebo-adjusted reduction in triglyceride levels in six months.

Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia (fasting triglycerides ≥150 mg/dL to

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

Ionis to host 2025 virtual Annual Meeting of Stockholders

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 5, 2025. The agenda for the event is as follows: 5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders All stockholders of record at the close of business on April 7, 2025, are invited to participate in the virtual Annual Meeting we.

Ionis to host 2025 virtual Annual Meeting of Stockholders

Zacks Investment Research

Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View

IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.

Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View

Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q1 2025 Earnings Conference Call April 30, 2025 11:30 AM ET Company Participants Wade Walke - SVP, IR Brett Monia - Founder, CEO & Director Kyle Jenne - EVP & Chief Global Product Strategy Officer Beth Hougen - EVP, Finance & CFO Jonathan Birchall - SVP & Chief Commercial Officer Eugene Schneider - EVP, Chief Clinical Development & Operations Officer Conference Call Participants Jay Olson - Oppenheimer Gary Nachman - Raymond James Debjit Chattopadhyay - Guggenheim Jessica Fye - JPMorgan Chi Meng Fong - Bank of America Merrill Lynch Yaron Werber - TD Cowen David Lebowitz - Citi Mani Foroohar - Leerink Mike Ulz - Morgan Stanley Operator Good morning, and welcome to the Ionis First Quarter 2025 Financial Results Conference Call. As a reminder, this call is being recorded.

Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript

Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge

Ionis Pharmaceuticals Inc IONS reported a first-quarter EPS loss of 93 cents on Wednesday, down from a loss of 98 cents, beating the consensus of a $1.12 loss.

Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge

Zacks Investment Research

Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks Investment Research

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $0.98 per share a year ago.

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Ionis reports first quarter 2025 financial results

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results for the first quarter ended March 31, 2025. “With an encouraging start to the TRYNGOLZA launch for familial chylomicronemia syndrome, the first of four independent launches expected over the next two years, Ionis' new chapter as a fully integrated, commercial-stage biotechnology company is well underway,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “We l.

Ionis reports first quarter 2025 financial results

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced results from a new survey showing that 91% of surveyed adults living with hereditary angioedema (HAE) were interested in trying a new prophylactic therapy, with nearly two-thirds (65%) reporting they haven't yet found the best treatment option for them. The Ionis-sponsored survey was conducted online by The Harris Poll among 150 adults living with HAE and 228 allergists/immunologists who see HAE patien.

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

See News Rankings

Charts implemented using Lightweight Charts™